Overcoming Barriers to Early Diagnosis and Optimizing Management of Idiopathic Hypersomnia: How Does Your Approach Compare to the Experts?
FACULTY
Karl Doghramji, MD, FAASM, DFAPA
Professor of Psychiatry and Human Behavior
Thomas Jefferson University
Jefferson Sleep Disorders Center
Philadelphia, PA
Richard K. Bogan, MD, FCCP, FAASM
Principal, Bogan Sleep Consultants, LLC
Associate Clinical Professor
Medical University of South Carolina, Charleston, SC
University of SC School of Medicine
Columbia, SC
PROGRAM DESCRIPTION
In this enduring activity, we will provide learners with an overview of idiopathic hypersomnia, focusing on early identification and diagnosis, and both nonpharmacologic and pharmacologic treatment options. We will help improve clinicians’ ability to distinguish between IH and other sleep disorders, interpret the latest efficacy and safety data for approved and off-label treatments, and understand the increased cardiovascular risk linked to IH and other sleep disorders.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of sleep specialists, pulmonologists, and other allied healthcare professionals who treat patients with idiopathic hypersomnia.
LEARNING OBJECTIVES
- Assess the impact of idiopathic hypersomnia (IH) on patients and the challenges associated with delayed diagnosis
- Adopt effective strategies for distinguishing between IH and other sleep disorders during differential diagnosis
- Discuss the latest efficacy and safety data guiding the utilization of approved therapies for IH
- Interpret the heightened cardiovascular risk linked to IH and identify optimal approaches for managing cardiovascular health in patients with IH
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
| Richard K. Bogan, MD, FCCP, FAASM | Consulting Fee | Jazz Pharmaceuticals, Harmony Biosciences, Avadel Pharmaceuticals, Alkermes, Takeda, Oventus, Easai, WaterMark Medical |
| Industry funded research | Avadel, Axsome, Bresotec, Bayer, Idorsia, Insilico, Fisher PAYKEL, Oura, ZIO, Suven, Jazz, Balance, NLS, Vanda, Merck, Eisai, Philips, Fresca, Rho, Takeda, Liva Nova, Roche, Sanofi, Sommetrics, Noctrix, | |
| Speakers Bureau | Axsome, Jazz, Eisai, Harmony, Idorsia, Watermark Medical. | |
| Karl Doghramji, MD | Consulting Fee | Jazz, Harmony, Biogen, Idorsia, Janssen, and Axsome |
| Contracted research | Inspire, Sommetrics, Respicardia, and Nyxoah | |
| Ownership Interest | Merck |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
- Sarah Milano RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
- Christopher J. Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Melissa A. Johnson, Program Director for Med Learning Group has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. ?In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group at info@medlearninggroup.com
RELEASED DATE: November 04, 2024
EXPIRATION DATE: November 04, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
